|
1
|
Hong SJ and Hong MK: Drug-eluting stents
for the treatment of coronary artery disease: A review of recent
advances. Expert Opin Drug Deliv. 19:269–280. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Hoole SP and Bambrough P: Recent advances
in percutaneous coronary intervention. Heart. 106:1380–1386.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Cao D, Chandiramani R, Chiarito M,
Claessen BE and Mehran R: Evolution of antithrombotic therapy in
patients undergoing percutaneous coronary intervention: A 40-year
journey. Eur Heart J. 42:339–351. 2021.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nso N, Nassar M, Zirkiyeva M, Mbome Y,
Lyonga Ngonge A, Badejoko SO, Akbar S, Azhar A, Lakhdar S, Guzman
Perez LM, et al: Factors impacting stent thrombosis in patients
with percutaneous coronary intervention and coronary stenting: A
systematic review and meta-analysis. Cureus.
14(e23973)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Loeffen R, Godschalk TC, van Oerle R,
Spronk HM, Hackeng CM, ten Berg JM and ten Cate H: The
hypercoagulable profile of patients with stent thrombosis. Heart.
101:1126–1132. 2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Towashiraporn K and Krittayaphong R:
Current perspectives on antithrombotic therapy for the treatment of
acute coronary syndrome. Int J Gen Med. 15:2397–2414.
2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Bocchino PP, Angelini F and Toso E: Atrial
fibrillation and coronary artery disease: A review on the optimal
use of oral anticoagulants. Rev Cardiovasc Med. 22:635–648.
2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Angiolillo DJ, Bhatt DL, Cannon CP,
Eikelboom JW, Gibson CM, Goodman SG, Granger CB, Holmes DR, Lopes
RD, Mehran R, et al: Antithrombotic therapy in patients with atrial
fibrillation treated with oral anticoagulation undergoing
percutaneous coronary intervention: A North American perspective:
2021 Update. Circulation. 143:583–596. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Karcioglu O, Zengin S, Ozkaya B, Ersan E,
Yilmaz S, Afacan G, Abuska D, Hosseinzadeh M and Yeniocak S: Direct
(new) oral anticoagulants (DOACs): Drawbacks, bleeding and
reversal. Cardiovasc Hematol Agents Med Chem. 20:103–113.
2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Bainey KR, Marquis-Gravel G, Mehta SR and
Tanguay JF: The evolution of anticoagulation for percutaneous
coronary intervention: A 40-year journey. Can J Cardiol. 38 (10
Suppl 1):S89–S98. 2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Erdoes G, Ortmann E, Martinez Lopez De
Arroyabe B, Reid C and Koster A: Role of bivalirudin for
anticoagulation in adult perioperative cardiothoracic practice. J
Cardiothorac Vasc Anesth. 34:2207–2214. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Zhang Y, Zhang Y, Chang C, Yan S, Chen Z,
Zhang L, Chen K and Liu G: Efficacy and safety of bivalirudin
during percutaneous coronary intervention in chronic total
occlusion: A retrospective study. Clin Ther. 43:844–851.
2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Mehran R, Lansky AJ, Witzenbichler B,
Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann
F, Gersh BJ, et al: Bivalirudin in patients undergoing primary
angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-Year
results of a randomised controlled trial. Lancet. 374:1149–1159.
2009.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li J, Chen S, Ma S, Yang M, Qi Z, Na K,
Qiu M, Li Y and Han Y: Safety and efficacy of bivalirudin versus
unfractionated heparin monotherapy in patients with CAD and DM
undergoing PCI: A retrospective observational study. Cardiovasc
Ther. 2022(5352087)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Han Y, Guo J, Zheng Y, Zang H, Su X, Wang
Y, Chen S, Jiang T, Yang P, Chen J, et al: Bivalirudin vs heparin
with or without tirofiban during primary percutaneous coronary
intervention in acute myocardial infarction: The BRIGHT randomized
clinical trial. JAMA. 313:1336–1346. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Chen S, Li Y, Qiu M, Jiang Z, Han Y and Li
J: Comparison of the effects of heparin and bivalirudin on
percutaneous coronary intervention in female patients with
coronary. Clin J Med Offic. 49:246–250, 253. 2021.
|
|
17
|
Subherwal S, Bach RG, Chen AY, Gage BF,
Rao SV, Newby LK, Wang TY, Gibler WB, Ohman EM, Roe MT, et al:
Baseline risk of major bleeding in non-ST-segment-elevation
myocardial infarction: The CRUSADE (can rapid risk stratification
of unstable angina patients suppress ADverse outcomes with early
implementation of the ACC/AHA guidelines) bleeding score.
Circulation. 119:1873–1882. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ki YJ, Lee BK, Park KW, Bae JW, Hwang D,
Kang J, Han JK, Yang HM, Kang HJ, Koo BK, et al: Prasugrel-based
de-escalation of dual antiplatelet therapy after percutaneous
coronary intervention in patients with STEMI. Korean Circ J.
52:304–319. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Mehran R, Rao SV, Bhatt DL, Gibson CM,
Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et
al: Standardized bleeding definitions for cardiovascular clinical
trials: A consensus report from the bleeding academic research
consortium. Circulation. 123:2736–2747. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Hamzah M, Jarden AM, Ezetendu C and
Stewart R: Evaluation of bivalirudin as an alternative to heparin
for systemic anticoagulation in pediatric extracorporeal membrane
oxygenation. Pediatr Crit Care Med. 21:827–834. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kimmelstiel C, Zhang P, Kapur NK,
Weintraub A, Krishnamurthy B, Castaneda V, Covic L and Kuliopulos
A: Bivalirudin is a dual inhibitor of thrombin and
collagen-dependent platelet activation in patients undergoing
percutaneous coronary intervention. Circ Cardiovasc Interv.
4:171–179. 2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hu YC, Yao WJ, Jin DX, Zhang JX, Wang L,
Zhang R, Xu JH and Cong HL: Bivalirudin in patients undergoing
percutaneous coronary intervention and independent predictors of
postoperative adverse events in these patients: A real world
retrospective study. Medicine (Baltimore).
100(e25003)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Yu XF, Chen HW, Xu J, Xu QZ, Zhang XH, Li
BB, Xu BL and Ma LK: Bivalirudin vs heparin on a background of
ticagrelor and aspirin in patients with ST-segment elevation
myocardial infarction undergoing primary percutaneous coronary
intervention: A multicenter prospective cohort study. Front
Cardiovasc Med. 9(932054)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Li Y, Liang Z, Qin L, Wang M, Wang X,
Zhang H, Liu Y, Li Y, Jia Z, Liu L, et al: Bivalirudin plus a
high-dose infusion versus heparin monotherapy in patients with
ST-segment elevation myocardial infarction undergoing primary
percutaneous coronary intervention: A randomised trial. Lancet.
400:1847–1857. 2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Shah A and Feldman DN: Outcome of the
HORIZONS-AMI trial: Bivalirudin enhances long-term survival in
patients with ST-elevation myocardial infarction undergoing
angioplasty. Vasc Health Risk Manag. 8:115–123. 2012.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Keating FK, Dauerman HL, Whitaker DA,
Sobel BE and Schneider DJ: The effects of bivalirudin compared with
those of unfractionated heparin plus eptifibatide on inflammation
and thrombin generation and activity during coronary intervention.
Coron Artery Dis. 16:401–405. 2005.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Saad M, Nairooz R, Rashed A, Abdelaziz HK,
Mentias A and Abbott JD: Bivalirudin versus heparin in women
undergoing percutaneous coronary intervention: A systematic review
and meta-analysis of randomized clinical trials. Cardiovasc Revasc
Med. 18:418–424. 2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Liang Z, Li Y, Wang J, Wang D, Wang S, Ma
L, Liu H, Yang L, Stone GW and Han Y: The safety and effectiveness
of bivalirudin in female patients with acute myocardial infarction
undergoing primary angioplasty: A subgroup analysis of the BRIGHT
trial. Catheter Cardiovasc Interv. 87 (Suppl 1):S608–S615.
2016.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chen H, Yu X, Kong X, Li L, Wu J and Ma L:
Efficacy and safety of bivalirudin application during primary
percutaneous coronary intervention in older patients with acute
ST-segment elevation myocardial infarction. J Int Med Res.
48(300060520947942)2020.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Widimský P: Is bivalirudin just an
expensive heparin? Eur Heart J. 37:1321–1324. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sun KX, Cui B, Cao SS, Wang WJ, Yu F, Wang
JW and Ding Y: A meta-analysis and cost-minimization analysis of
bivalirudin versus heparin in high-risk patients for percutaneous
coronary intervention. Pharmacol Res Perspect.
9(e00774)2021.PubMed/NCBI View
Article : Google Scholar
|
|
32
|
Amin AP, Marso SP, Rao SV, Messenger J,
Chan PS, House J, Kennedy K, Robertus K, Cohen DJ and Mahoney EM:
Cost-effectiveness of targeting patients undergoing percutaneous
coronary intervention for therapy with bivalirudin versus heparin
monotherapy according to predicted risk of bleeding. Circ
Cardiovasc Qual Outcomes. 3:358–365. 2010.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Schwenkglenks M, Toward TJ, Plent S, Szucs
TD, Blackman DJ and Baumbach A: Cost-effectiveness of bivalirudin
versus heparin plus glycoprotein IIb/IIIa inhibitor in the
treatment of acute ST-segment elevation myocardial infarction.
Heart. 98:544–551. 2012.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mehrzad M, Tuktamyshov R and Mehrzad R:
Safety, efficiency and cost effectiveness of bivalirudin: A
systematic review. World J Cardiol. 9:761–772. 2017.PubMed/NCBI View Article : Google Scholar
|
